Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 27.47 5.49% 1.43
DCPH closed up 5.49 percent on Friday, January 19, 2018, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical DCPH trend table...

Date Alert Name Type % Chg
Jan 19 New 52 Week Closing High Bullish 0.00%
Jan 19 New 52 Week High Strength 0.00%
Jan 19 Stochastic Reached Overbought Strength 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 19 Up 3 Days in a Row Strength 0.00%
Jan 18 New 52 Week High Strength 5.49%
Jan 18 Wide Bands Range Expansion 5.49%
Jan 18 Overbought Stochastic Strength 5.49%
Jan 17 Wide Bands Range Expansion 9.97%

Older signals for DCPH ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.53
52 Week Low 15.15
Average Volume 173,520
200-Day Moving Average 0.0
50-Day Moving Average 20.5282
20-Day Moving Average 23.8725
10-Day Moving Average 25.393
Average True Range 1.6378
ADX 35.46
+DI 26.86
-DI 9.86
Chandelier Exit (Long, 3 ATRs ) 22.6166
Chandelier Exit (Short, 3 ATRs ) 20.9934
Upper Bollinger Band 28.518
Lower Bollinger Band 19.227
Percent B (%b) 0.89
BandWidth 38.919259
MACD Line 1.7219
MACD Signal Line 1.5936
MACD Histogram 0.1283
Fundamentals Value
Market Cap 876.98 Million
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -1.71
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.34
Resistance 3 (R3) 30.04 28.78 29.86
Resistance 2 (R2) 28.78 28.05 28.93 29.70
Resistance 1 (R1) 28.13 27.60 28.46 28.43 29.54
Pivot Point 26.87 26.87 27.04 27.02 26.87
Support 1 (S1) 26.22 26.14 26.55 26.52 25.40
Support 2 (S2) 24.96 25.69 25.11 25.24
Support 3 (S3) 24.31 24.96 25.08
Support 4 (S4) 24.61